EVH Evolent Health Inc

Evolent Health announced that Cheryl Scott retired from its Board of Directors and Jill Smith was appointed as a new independent director. The company also reaffirmed its fourth-quarter 2025 revenue guidance of $462.0 million to $472.0 million and Adjusted EBITDA guidance of $30.0 million to $40.0 million. This guidance is consistent with its previous outlook from November 6, 2025.

Evolent Health (NYSE:EVH) insiders recently bought $1.38 million worth of shares, though their investment is still down by $709k. Despite the losses, their purchases, including a significant one by Co-Founder Seth Blackley at a higher price, indicate a belief in the company's future. Insider ownership stands at 1.8%, valued at $8.1 million.

Evolent Health (NYSE: EVH) and American Oncology Network (AON) have announced a national partnership to deploy a quality-focused cancer care model that aims to reduce costs, speed treatment, and eliminate prior authorization for providers who meet quality standards. Key elements include "gold-carding" providers, an AI analytics platform called MiBA for personalized treatment insights, and Evolent's Careology navigation program. The model, set to roll out in select markets in the year ahead, seeks to improve clinical decision-making and reward high-quality care.

Piper Sandler maintained a Buy rating on UnitedHealth (UNH) with a price target of $423.00, while Morgan Stanley also issued a Buy rating. However, TD Cowen maintained a Hold rating on the stock. Insider sentiment for UNH is currently negative, with some insiders selling shares recently.

Evolent Health (NYSE: EVH) is projected to report a 24.8% year-on-year revenue decline to $467.3 million for Q3 2025, with adjusted earnings around $0.11 per share. The company has previously missed revenue expectations, and its stock has dropped 20.6% in the last month, contrasting with some peers in the healthcare technology segment. The average analyst price target is significantly higher than its current share price.

This article provides a detailed analysis of Evolent Health Inc (EVH) with a focus on AI-generated trading signals and risk zones. It highlights weak sentiment across all time horizons, suggesting a short bias, and presents specific trading strategies (Long, Breakout, Short) with entry points, targets, and stop losses. The analysis also includes multi-timeframe signal strength, support, and resistance levels.